At the very beginning of this year, I wrote an HHCN+ Report on the home Health public market and how it sets the pace for the rest of the industry.
At the time, the public companies were all doing well, though things have certainly changed since then. Among my takeaways, I wrote about how larger providers were focused on building geographic density in 2022 and how new public players were shaking things up.
I also wrote about how, over time, the largest providers in home health care had gone from generally conservative entities to companies with greater aspirations and less risk-averse attitudes.
A prime example of that was Amedisys Inc. (Nasdaq: AMED).
Sign up for HHCN + to read this exclusive content.
Individual Membership
$400 per year
Purchase
Group
2–5 members
$380 per year*
Purchase
Need more than 5 members? Contact us for more information.
* per member
Already a member?
The post Why the Proposed Rule Could Hinder the Home Health Public Market’s Strategic Visions appeared first on Home Health Care News.
